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ABSTRACT
Osteoporosis and its associated fractures are highly prevalent in older women. Recent studies have shown that gut microbiota play
important roles in regulating bone metabolism. A previous randomized controlled trial (RCT) found that supplementation with Lac-
tobacillus reuteri ATCC PTA 6475 (L.reuteri) led to substantially reduced bone loss in older women with low BMD. However, the total
metabolic effects of L. reuteri supplementation on older women are still not clear. In this study, a post hoc analysis (not predefined) of
serummetabolomic profiles of older women from the previous RCT was performed to investigate themetabolic dynamics over 1 year
and to evaluate the effects of L. reuteri supplementation on human metabolism. Distinct segregation of the L. reuteri and placebo
groups in response to the treatment was revealed by partial least squares-discriminant analysis. Although no individual metabolite
was differentially and significantly associated with treatment after correction for multiple testing, 97 metabolites responded differ-
entially at any one time point between L. reuteri and placebo groups (variable importance in projection score >1 and p value
<0.05). These metabolites were involved in multiple processes, including amino acid, peptide, and lipid metabolism. Butyrylcarnitine
was particularly increased at all investigated time points in the L. reuteri group compared with placebo, indicating that the effects of
L. reuteri on bone loss are mediated through butyrate signaling. Furthermore, the metabolomic profiles in a case (low BMD) and con-
trol population (high BMD) of elderly women were analyzed to confirm the associations between BMD and the identifiedmetabolites
regulated by L. reuteri supplementation. The amino acids, especially branched-chain amino acids, showed association with L. reuteri
treatment and with low BMD in older women, and may serve as potential therapeutic targets. © 2021 The Authors. JBMR Plus pub-
lished by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
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Introduction
Osteoporosis is a disease characterized by reduced BMD,deteriorated bone microarchitecture, and reduced bone
strength, which increases the susceptibility to low energy or fra-
gility fractures primarily affecting the older population.(1,2) Accu-
mulating evidence has revealed that the gut microbiota is a key
regulator of bone metabolism and could affect bone health.(3-6)
Previous studies in mice have revealed that gut microbiota influ-
ences bone health by the regulation of the immune system and
balance.(7) The supplementation of probiotic strain Lactobacillus
reuteri ATCC PTA 6475 (L. reuteri) has been shown to reduce bone
loss and increase bone density in mice with estrogen deficiency
or increased inflammation.(8,9) These data suggest that L. reuteri
may be a potential therapeutic strategy to prevent postmeno-
pausal bone loss.
In our previous study, we observed that supplementation with
L. reuteri could reduce bone loss by approximately 50% in older
women with low BMD.(10) In mice, probiotic supplements affect
bone metabolism via the production of short chain fatty acids
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in the intestine.(7) However, themechanisms related to the effect
of the different probiotic supplementations on human metabo-
lism remains unknown. An understanding of the dynamic meta-
bolic changes incurred by probiotic supplementation may
provide new insights into the regulation of bone metabolism
and could be crucial for the development of novel osteoporosis
treatments. Untargeted metabolomics have provided an oppor-
tunity to investigate the global metabolic changes in human
populations.(11,12) Although the existing metabolomic studies
related to osteoporosis have been performed in rats and
humans,(13-16) the effects of probiotic supplementation on
human bone metabolism have not been explored. Therefore,
we investigated the effect of daily supplementation with
L. reuteri or placebo on serum metabolomic profiles in older
women who had been included in a 1-year randomized con-
trolled trial (RCT) in a nonpredefined post hoc analysis.(10) We fur-
ther examined differences in metabolic profiles between older
women with severe osteoporosis (case group) and high bone
density (control group).
In this study, we identified the key serum metabolic makers
that were regulated by L. reuteri treatment and discriminated
subjects with severe osteoporosis from controls. We found that
amino acids and peptides not only were regulated by treatment
with L. reuteri, but also differed in bone loss between the control
and case group. Interestingly, butyrylcarnitine (C4) showed a
robust increase in subjects who had had L. reuteri treatment.
Thus, the present study’s results suggest that the affected meta-
bolic pathways by L. reuteri contribute to the regulation of bone
loss in older women.
Patients and Methods
Study populations
As previously described,(10) we studied the per protocol popula-
tion in a placebo-controlled cohort (68 elderly women with
osteopenia who completed the study and had not used medica-
tion in violation of the study protocol), of whom32 had been ran-
domized to treatment with L. reuteri and 36 to placebo. In
addition, we set-up a separate cross-sectional study to investi-
gate case and matched controls of 240 elderly women, of whom
120 had high BMD and 120 had very low BMD. Information
regarding previous fragility fractures was obtained using ques-
tionnaires. The case and control groups were selected from the
population-based SUPERB (Sahlgrenska University Hospital Pro-
spective Evaluation of Risk of Bone Fractures) cohort (from
2013–2016) of 3028 women who were 75 to 80 years old,(17) by
identifying the 120 women with the lowest tibia total volumetric
BMD (total vBMD; case group) andmatching them to 120women
with the highest tibia volumetric BMD (control group) by age,
height, weight, and BMI, using propensity score matching with
R package MatchIt.(18)
Measurements of bone traits, body composition, and
serum markers
The lower leg (tibia) of the nondominant side (based on the
dominant arm) was measured to determine bonemicrostructure
and geometry, using HR-pQCT (Xtreme CT; Scanco Medical AG).
All measurement procedures were performed according to
instructions and protocols from the manufacturer.(19) A three-
dimensional construction of the bone was assembled using
110 slices obtained from each measurement. The nominal
isotropic resolution was 82 μm. After image processing,(20) the
following variables were obtained: total volumetric BMD (total
vBMD, mg/cm3), trabecular bone volume fraction (BV/TV, %), cor-
tical thickness (Ct.Th, mm), and cortical volumetric BMD (Ct.
vBMD, mg/cm3). Image quality was assessed and quality was
graded from 1 to 5; a perfect quality was defined as 1 and a sub-
optimal quality was 5. Only images with a quality level between
one and three were used for analysis. The coefficients of varia-
tion (CV) for the generated bone variables at the tibia ultradistal
site were 0.2% for the tibia total vBMD for 0.5% for the BV/TV,
0.5% for Ct.Th, and 0.3% for the Ct.vBMD.
Areal BMD (aBMD, g/cm2) was measured at the lumbar spine
(L1–L4), total hip, femoral neck, and body composition of the
total body was determined with a Hologic Discovery A DEXA
(Hologic). The CVs for aBMD were 0.7% for lumbar spine, 0.8%
for total hip, and 1.3% for the femoral neck.(10)
N-telopeptide of type I collagen (NTx; Osteomark; Alere Scar-
borough, Inc; intra- and interassay variability of 4.6 and 6.9%,
respectively), bone-specific alkaline phosphatase (BAP; Micro-
vue; Quidel Corp; intra- and interassay variability of 5.0 and
5.9%, respectively), ultrasensitive C-reactive protein (usCRP; Bio-
Merica, Inc; intra- and interassay variability of 4.4 and 3.3%,
respectively) and TNF-α (Quantikine; R&D Systems, Inc; intra-
and interassay variability of 2.0 and 6.7%, respectively) were
measured in duplicate by TECO Medical AG.
Serum sample preparation and metabolomic profiling
Serum samples were collected from the case and control sub-
jects (240 elderly women) at fasting, as well as from women in
the L. reuteri and placebo arms of the RCT (68 elderly women)
at four time points: month 0 (baseline), 3, 6, and 12. Serum sam-
ples were frozen immediately after collection and stored in
−80C until analysis. The metabolomics analysis was performed
blinded to study group. Metabolomics were performed using liq-
uid chromatography-tandem mass spectroscopy (LC–MS) at
Metabolon, Inc, with their standard and platform method (Sup-
plementary Materials and Methods).(21) Peak intensities of all
metabolites in original scale (provided by Metabolon; Supple-
mentary Information Data Set) were analyzed. First, we used an
imputationmethod drawing random values from the normal dis-
tribution to simulate signals from low abundant metabolites that
were assumed to give rise to missing values.(22) The width of the
normal distribution was set as 0.5 times the SD of all measured
values, and the center was downshifted by 2.5 times of the
SD. Second, metabolites with <25% missing values across all
samples were selected and analyzed further, which enabled
the identification of important metabolites with high confi-
dence. Finally, peak intensities of the filtered metabolites within
sample i (i = 1, 2, 3…n; n is the total number of samples) were
normalized to the total intensity. This normalization method
considered the differences of sample volume used in LC–MS
and assumes that all samples have equal total intensity.(23) The
normalization process included the following steps: (i) the total
intensity of sample i was summed up; (ii) the correction factor
of sample i was calculated by dividing the total intensity with
the lowest total intensity of all samples; and (iii) peak areas of
all metabolites within sample iwere divided by its individual cor-
rection factor. The normalized metabolite abundance was log-
transformed if necessary. Three subjects (LB36, LB44, LB56) with
incomplete serum samples obtained during follow-up were
excluded from metabolomics analysis.
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Statistical analysis
To evaluate the effects of L. reuteri on metabolites during the
1-year intervention, we calculated the metabolite levels at differ-
ent time points as a ratio of the baseline value, and then the
ratios between L. reuteri and placebo groups were compared
using the two-tailed Wilcoxon rank-sum test. In comparisons
between the two groups at each time point, we performed
993 tests for the metabolites with <25%missing values obtained
after data normalization. The p values were adjusted by the false
discovery rate (FDR) or Bonferroni test to control for multiple-
comparison error using R function p.adjust (Supplemental
Table 1. Baseline Characteristics of the Lactobacillus reuteri 6475 Placebo-Controlled Randomized Controlled Trial Cohort
Characteristics L. reuteri (N = 32) Placebo (N = 36)
Age, y 76.3  0.9 76.2  1.1
Height, cm 162.3  4.8 164.0  5.7
Weight, kg 67.0  8.3 68.2  10.5
BMI, kg/m2 25.5  3.4 25.3  3.5
BMD, T score
Lumbar spine −0.86  0.98 −0.99  0.91
Total hip −1.05  0.71 −1.18  0.52
Femoral neck −1.60  0.62 −1.70  0.64
HR-pQCT–derived bone variables
Total tibia volumetric BMD, mg/cm3 235  42.2 231  45.6
Trabecular bone volume fraction, % 12.2  2.2 12.6  2.4
Cortical volumetric BMD, mg/cm3 767  67.0 740  66.0
Cortical thickness, mm 0.81  0.2 0.76  0.3
Serum markers
N-terminal telopeptide, nM 14.3  3.5 15.6  8.0
Bone-specific alkaline phosphatase, U/L 17.2  4.2 18.0  6.7
C-reactive protein, mg/La 1.34 (0.80–2.86) 1.36 (0.75 to 3.63)
TNF-α, pg/mL 1.34  0.4 1.30  0.3
Body composition, kg
Total fat mass 25.0  5.9 25.8  6.7
Total lean mass 42.4  3.4 42.7  5.2
Note: Mean  SD. The characteristics of the per protocol population were calculated.(10)
aNonnormally distributed variables are presented as median with interquartile range.
Table 2. Clinical Characteristics of the Case and Control Groups
Characteristics
Case (Low BMD) Control (High BMD)
p Valued(N = 120) (N = 120)
Age, y 78.14  1.6 78.21  1.72 0.75
Height, cm 1625.84  64.99 1624.35  57.32 0.85
Weight, kg 64.2  11.07 64.92  9.61 0.59
BMI, kg/m2 24.27  3.83 24.6  3.44 0.47
Total tibia volumetric BMD, mg/cm3 157.4  21.92 267.76  29.58 <0.001
BMD
Lumbar spine (L1–L4), g/cm2 0.82  0.13 1.00  0.16 <0.001
Lumbar spine T score −2.04  1.16 −0.39  1.50 <0.001
Total hip, g/cm2 0.69  0.1 0.87  0.1 <0.001
Total hip T score −2.07  0.81 −0.62  0.86 <0.001
Femoral neck, g/cm2 0.58  0.09 0.72  0.09 <0.001
Femoral neck T score −2.31  0.78 −1.19  0.79 <0.001
Fracture risk assessment tool scorea 34.15  13.59 16.65  8.16 <0.001
Prevalent fracture, no. (%)b 111 (92.5) 0 (0) <0.001
Physical health—physical component scorec 45.52  11.16 47.71  9.5 0.1
Note: Mean  SD.
aTen-year probability of major osteoporotic fracture, calculated with femoral neck BMD.
bAny clinical prevalent fracture after age 50 years.
cPhysical component score derived from the 12-Item Short Form Health Survey.
dp Values were derived from Student’s t test for continuous variables or from Fisher’s exact test for dichotomous variables. The characteristics signifi-
cantly different (p < 0.001) between case and control groups are highlighted in bold.
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Table 2). To distinguish metabolomic responses (namely relative
changes from baseline) in the L. reuteri group from the placebo
group, partial least squares-discriminant analysis (PLS-DA) were
performed using the mixOmics package with default parame-
ters.(24) The response of a metabolite was considered to be the
differential between the placebo and L. reuteri groups at any
one time point when the metabolite was qualified by using the
cut-off of a variable importance in projection (VIP) score >1 in
the PLS-DA model and p value <0.05 in the Wilcoxon rank-
sum test.
To assess the associations between metabolites and clinical
variables, we performed the Pearson’s correlation analysis and
hierarchical clustering with default parameters. The p values
were adjusted by the FDR to correct for multiple testing. To iden-
tify different response patterns during the 1-year intervention, a
clustering analysis of the metabolites that responded differently
between the L. reuteri and placebo groups was performed. The
cluster::diana function was used based on a correlation coeffi-
cients matrix as a distance measure, and then by cutting the tree
using the divisive coefficient of the clustering. For each cluster of
metabolites, only the ones with a minimum cluster size of
10 metabolites were selected. To visualize the metabolic differ-
ence between the case group and the control group, a principal
components analysis (PCA) and a PLS-DA were performed. The
fold changes of metabolites between the case and control
groups were compared using linear regression models adjusted
by covariates’ age and BMI. In total, we performed 1007 tests for
the metabolites with <25% missing values obtained after data
normalization. The p values were adjusted by the FDR or a Bon-
ferroni test to control for multiple-comparison error (Supplemen-
tal Table 4). Differential metabolites between the case and
control groups were identified by using the VIP score cut-off of
>1 in PLS-DA and p value <0.05 in the fold changes of
metabolites.
To discriminate the BMD status of the case subjects from the
controls, a random forest model was trained based on metabo-
lite profiles using the randomForest package in R with default
parameters and 1000 trees. To determine the contribution of
metabolites to the classification models, the metric “mean
decrease in accuracy” was calculated, and the performance of
the predictive model was evaluated by the receiver operating
characteristic (ROC) analysis and the area under the ROC
curve (AUC).
Pathway analysis of the metabolites was performed using a
web-based tool MetaboAnalyst 4.0 (https://www.metaboanalyst.
ca).(25) The significant enrichment of pathways was determined
by Fisher’s exact test (p value <0.05).
Results
Global metabolic shifts in L. reuteri 6475
placebo-controlled RCT cohort
Over a follow-up period of 1 year, we collected serum samples
from 32 subjects with L. reuteri supplementation and 36 subjects
with placebo. The demographic and clinical characteristics of these
68 subjects at baseline are given in Table 1 and have been previ-
ously described.(10) There were no significant differences in the
clinical characteristics between the L. reuteri and placebo groups
at baseline. The design of the study is depicted in Fig. 1A. Overall,
we collected 269 serum samples from these subjects during 1-year
follow-up at four time points: baseline; 3, 6, and 12 months. The
resulting metabolomics data set comprised a total of 1232 metab-
oliteswith 958 compounds of known identity (namedmetabolites)
and 274 compounds of unknown structural identity (unnamed
metabolites), which were measured by LC–MS. After data normal-
ization, we obtained measurements for 993 metabolites with
<25% missing values for downstream analyses. As shown in
Fig. 1B, we calculated the Euclidean distances between L. reuteri
and placebo groups at different time points based on metabolic
profiles and performed hierarchical clustering analysis. It was clear
that L. reuteri and placebo groups clustered together at baseline,
which showed higher metabolic similarity and agreement with
similar clinical parameters. In addition, metabolic profiles exhibited
differences between the L. reuteri and placebo groups in the
follow-up period.
Table 3. The Differential Pathways Between the Case and Control Groups
KEGG pathway Totala Hitsb Metabolites p Valuec
Adjusted
p Valued Impacte
Aminoacyl-tRNA biosynthesis 75 5 Arginine, valine, lysine, leucine,
glutamate
0.005 0.30 0.113
Valine, leucine, and isoleucine
biosynthesis
27 3 Leucine, 3-methyl-2-oxobutyrate,
valine
0.007 0.30 0.115





Butanoate metabolism 40 3 Glutamate, maleate, fumarate 0.022 0.36 0.038
Valine, leucine, and isoleucine
degradation
40 3 Leucine, valine, 3-methyl-2-oxobutyrate 0.022 0.36 0.039
Arginine and proline metabolism 77 4 Arginine, glutamate, creatinine,
fumarate
0.028 0.38 0.169
Citrate cycle (TCA cycle) 20 2 Malate, fumarate 0.036 0.42 0.060
aIt is the total number of metabolites present in the KEGG pathway.
bIt is the number of metabolites matched into the corresponding pathway.
cThe p values were calculated from the enrichment analysis.
dThe adjusted p values were obtained using false discovery rate correction.
eThe pathway impact values were calculated from a pathway topology analysis.
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Table 4. The Differential Metabolites Between the Case (Low BMD) and Control Groups (High BMD) and Simultaneously AssociatedWith
the Lactobacillus reuteri Supplementation
Metabolites Class VIP scorea FCb p Valuec
Adjusted
p Valued R_3e R_6e R_12e
N,N,N-trimethyl-alanylproline betaine (TMAP) Amino acid 1.31 0.93 0.031 0.41 Up - -
Valine Amino acid 1.80 0.93 0.0049 0.24 - Up -
Cysteine S-sulfate Amino acid 1.17 0.85 0.049 0.48 Down - Down
Isovalerylcarnitine (C5) Amino acid 1.57 0.89 0.0071 0.28 Up - -
Deoxycarnitine Lipid 1.48 0.94 0.026 0.41 - Up -
Sphingomyelin (d17:2/16:0, d18:2/15:0)* Lipid 1.30 0.92 0.039 0.44 - Down -
Sphingomyelin
(d18:1/22:2, d18:2/22:1, d16:1/24:2)*
Lipid 1.33 0.94 0.048 0.48 - Down -
Sphingomyelin (d18:2/21:0, d16:2/23:0)* Lipid 1.63 0.91 0.0064 0.26 - Down -
Sphingomyelin (d18:2/23:1)* Lipid 1.38 0.94 0.039 0.44 - Down -
Fibrinopeptide A (3-15) Peptide 1.63 0.84 0.0053 0.24 Down - -
Gamma-glutamyl-alpha-lysine Peptide 1.57 0.94 0.02 0.37 - Up -
Gamma-glutamyl leucine Peptide 1.37 0.94 0.043 0.46 Up Up -
aThe variable importance in projection (VIP) scores were obtained from the partial least squares-discriminant analysis model.
bFold change (FC) was calculated by dividing the mean value of metabolite levels in the case group with the control group.
cThe p values were derived from linear regression model, adjusted by for BMI and age.
dThe adjusted p values were obtained using false discovery rate correction.
eR_3, R_6, R_12 represented differential responses to treatment with L. reuteri at 3, 6, and 12 months, respectively. Up and Down indicates upregulated
and downregulated, respectively (p value < 0.05). “-” indicates insignificantly differential responses.
Fig 1. The metabolomic profiling of the cohort supplemented with placebo or Lactobacillus reuteri. (A) The scheme diagram of experimental design.
Serum samples were collected from older women with bone loss at baseline, and 3, 6, and 12 months later. (B) The heatmap shows the hierarchical clus-
tering of Euclidean distances between serum samples. (C) Numbers of significantly differential metabolites among all time points in the L. reuteri group
and placebo group (adjusted p < 0.1 with false discovery rate by the Wilcoxon signed-rank test) are shown.
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The dynamic alterations of metabolomic profiles in
L. reuteri and placebo groups during follow-up
To investigate how the human serummetabolome changed dur-
ing the 1-year follow-up, we first identified differences between
two sampling time points in the L. reuteri or placebo groups,
respectively. The significantly differential metabolites over time
in each group are shown in Fig. 1C and Supplementary Informa-
tion Table S1 (adjusted p < 0.1 with FDR by the Wilcoxon signed-
rank test). Over the course of the intervention, 67 (7 upregulated
and 60 downregulated), 33 (2 upregulated and 31 downregu-
lated), and 41 (10 upregulated and 31 downregulated) metabo-
lites were significantly differential at 3, 6, and 12 months,
respectively, comparedwith baseline in the placebo group, while
a few metabolites were detected differentially in the L. reuteri
group. Less metabolic variations were observed when compar-
ing different sampling time points after baseline in both
L. reuteri and placebo groups. In addition, there were only three
common metabolites that changed significantly over time both
in the L. reuteri and placebo groups.
Differential metabolic responses linked to probiotic
supplementation
Next, we investigated whether probiotic-specific responses
occurred during 1 year, which might promote our understanding
of the mechanistic effects of L. reuteri on human metabolism.
Therefore, we first calculated the metabolite level at follow-up
time points as a ratio of the baseline value that was referred to
as the metabolic response to the treatment. Then, the variances
in the metabolic response were investigated by PLS-DA. The
PLS-DA results revealed a distinct segregation of the L. reuteri
and placebo groups in response to treatment at 3, 6, and
12 months, respectively (Fig. 2A-C). We further identified metabo-
lites that showed differences in relative change from baseline
between L. reuteri and placebo groups by the Wilcoxon rank-
sum test. There were no significant metabolites identified when
we corrected for multiple testing (adjusted p < 0.1). In total,
97 metabolites responded differentially at any one time point
between L. reuteri and placebo groups, when using the cutoff of
both VIP score cut-off of >1 in the PLS-DA model and p value
Fig 2. The differential responses to the treatment with Lactobacillus reuteri. The score plots of partial least squares-discriminant analysis models discrim-
inating the L. reuteri group from the placebo group based on metabolic responses (i.e., changes from baseline) at 3 (A), 6 (B), and 12 (C) months, respec-
tively. (D) The metabolites differed in changing from baseline between L. reuteri and placebo groups at 3, 6, and 12 months (variable importance in
projection score >1 and p value <0.05). (E) The relative changes from baseline (mean ± SE) of butyrylcarnitine (C4) and 1-methyl-4-imidazoleacetate that
responded differentially between the L. reuteri and placebo groups at all time points are shown. * p < 0.05; **p < 0.01; ***p < 0.001.
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<0.05 in the Wilcoxon rank-sum test (Supplementary Information
Table S2 and Supplementary Information Fig. S1). There were
30, 54, and 31 metabolites that changed from baseline differen-
tially between L. reuteri and placebo groups at 3, 6, and
12 months, respectively (Fig. 2D). Of these, 16 metabolites were
changed differentially between L. reuteri and placebo groups at
two follow-up time points. Interestingly, two metabolites (butyryl-
carnitine (C4) and 1-methyl-4-imidazoleacetate) responded differ-
entially at three follow-up time points (Fig. 2E). Most of the
identified 97 metabolites are known to be involved in biological
processes, including lipid, amino acid, peptide, and cofactors
metabolism (Supplementary Information Fig. S2).
Associations between metabolic levels and clinical
outcomes
The associations between 16 clinical variables at baseline and
12 months were examined, respectively (Supplementary
Information Fig. S3). At baseline, total tibia vBMD, cortical vBMD,
and cortical thickness were associated positively with usCRP,
which is a marker of inflammation (adjusted p < 0.1). After a
12-month intervention, we did not observe significant associa-
tions between usCRP and bone-related traits. Total body weight,
fat mass, and BMI were positively associated with usCRP and
TNF-α at both time points (adjusted p < 0.05). In addition, two bio-
chemical markers of bone turnover, BAP and NTX, were associated
negatively with bone-related traits, such as total tibia vBMD and
cortical vBMD, which were consistent with previous results.(26-29)
To investigate associations between clinical outcomes and the
metabolites that responded differently between L. reuteri and pla-
cebo groups, we calculated the Pearson’s correlation coefficients
between clinical characteristics and differential metabolites at
baseline and 12 months, respectively. We found that 13 and
9 metabolites were correlated (p < 0.05) with total tibia vBMD at
baseline and 12 months, respectively (Supplementary
Information Fig. S4 and Fig. 3A). Out of them, 1-methyl-4-imidazo-
leacetate, 1-ribosyl-imidazoleacetate*, isovalerylglycine, and pro-
line were positively associated with total tibia vBMD at baseline.
Gamma-glutamyl leucine, 2-methylbutyrylcarnitine (C5), and cys-
teine S-sulfate were associated with total tibia vBMD at
12 months. Interestingly, isovalerylcarnitine (C5) was positively
correlated with total tibia vBMD at both baseline and 12 months.
In addition, one class of metabolites, including 1-methyl-4-imida-
zoleacetate, 1-ribosyl-imidazoleacetate*, gamma-glutamyl leu-
cine, and 2-methylbutyrylcarnitine (C5) were not only positively
associated with total tibia vBMD, but also with TNF-α and BMI at
baseline or 12 months.
Dynamic patterns of differential metabolites associated
with L. reuteri supplementation
Clustering analyses were performed to identify different alter-
ation trends of metabolites in response to supplementation with
L. reuteri or placebo. The differential metabolites were clustered
into mainly four different response patterns (Fig. 3B). The class
information of metabolites in each cluster is shown in Fig. 3C.
Cluster 1 (n = 15) showed reduced levels in the L. reuteri group
in comparison with the placebo group and enrichment in the
metabolism of sphingomyelins, which were decreased in the
early stage and then increased at 6 months. Cluster 2 (n = 15)
increased and peaked at 6 months in the L. reuteri group,
whereas it was steady in the placebo group. In this cluster, similar
responses were found for four metabolites involved in amino
acid metabolism: 1-methyl-4-imidazoleacetate, 1-ribosyl-imi-
dazoleacetate*, N,N,N-trimethyl-alanylproline betaine (TMAP),
and N6,N6-dimethyllysine. Besides, two peptides gamma-gluta-
myl-alpha-lysine and gamma-glutamyl tryptophan reacted very
similarly to the intervention. Metabolites of cluster 3 (n = 25)
were reduced at 3 months and then showed increased levels in
both groups, although at higher levels in the L. reuteri group. In
addition, metabolites of cluster 4 (n = 10) increased over time
in the L. reuteri group, whereas they decreased in the placebo
group. In this cluster, four metabolites associated with lipid
metabolism, butyrylcarnitine (C4), glycerol, heptenedioate
(C7:1-DC)*, and androsteroid monosulfate C19H28O6S (1)*,
responded differentially between L. reuteri and placebo groups.
Thus, by using clustering analysis more insights were provided
into the affected biological processes having similar regulation
during the 1-year intervention.
Metabolic pathways affected by treatment with L. reuteri
The important metabolites that differed in response to supple-
mentation with L. reuteri and placebo at any one time point
(VIP score >1 and p value <0.05) and the related metabolic path-
ways are described in detail below.
Amino acid metabolism
Among the 97 differential metabolites, 15 of them were involved
in amino acid metabolism. The plasma levels of three amino acids,
including proline, threonine, and valine, showed a different
response between the L. reuteri and placebo groups
(Supplementary Information Fig. S5A-C). They all showed
increased trends after supplementation with L. reuteri compared
with placebo. In response to probiotic supplementation, isovaler-
ylcarnitine (C5), 2-methylbutyrylcarnitine (C5), and isovalerylgly-
cine, involved in branched chain amino acid (BCAA) metabolism,
exhibited differences between L. reuteri and placebo groups
(Supplementary Information Fig. S5D-F). Subjects in the L. reuteri
group had higher levels of BCAA-derived metabolites in compari-
son with the placebo group. The level of cysteine S-sulfate related
to cysteine metabolism decreased in response to treatment with
L. reuteri compared with the placebo group (Supplementary
Information Fig. S5G). Simultaneously, the level of cysteine S-
sulfate correlated negatively with total tibia vBMD at 12 months
(Fig. 3A). In addition, 1-methyl-4-imidazoleacetate and 1-ribosyl-
imidazoleacetate*, involved in histidine metabolism, showed
increased levels in the L. reuteri group compared with the placebo
group (Fig. 2E and Supplementary Information Fig. S5H). Simulta-
neously, they were associated positively (r = 0.3 and r = 0.34,
respectively; p < 0.05) with total tibia vBMD at baseline
(Supplementary Information Fig. S4). Conversely, the levels of
indolepropionate and indole-3-carboxylate, involved in trypto-
phan metabolism, was at a steady level in the L. reuteri group,
whereas it increased over time in the placebo group
(Supplementary Information Fig. S5I,J).
Peptide metabolism
The plasma levels of four peptide metabolites, gamma-glutamyl-
alpha-lysine, gamma-glutamyl leucine, gamma-glutamyl threo-
nine, and gamma-glutamyl tyrosine, showed different responses
between the L. reuteri and placebo groups (Supplementary
Information Fig. S6A-D). They all showed increased levels com-
pared with the placebo group. This indicates an increased
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uptake of amino acids in the L. reuteri group in comparison with
the placebo group (Supplementary Information Fig. S5A-C).
Lipid metabolism
Several metabolites in the fatty acid subclass that responded dif-
ferentially between the L. reuteri and placebo groups were iden-
tified. Butyrylcarnitine (C4), caprate (10:0), 2-hydroxydecanoate,
heptenedioate (C7:1-DC)*, and octadecenedioate (C18:1-DC)*
showed increased levels compared with the placebo group
(Fig. 2E and Supplementary Information Fig. S7A-D). Moreover,
the levels of succinylcarnitine (C4) and deoxycarnitine, which
are involved in carnitine metabolism, increased compared with
the placebo group (Supplementary Information Fig. S7E,F). In
addition, the glycerol level was increased in the L. reuteri group
compared with the placebo group, which indicates that the
Fig 3. (A) The Pearson’s correlation coefficients between 16 clinical variables and 9 BMD-associated metabolites at 12 months are shown. +p < 0.05;
*adjusted p < 0.1; **adjusted p < 0.05. The false discovery rate was used to correct for multiple testing. (B) Clustering of differential metabolites potentially
mediated by Lactobacillus reuteri supplementation. Four clusterswere identifiedwith different response patterns over time in L. reuteri and placebogroups. (C)
The class information ofmetabolites in each cluster (detailed information is listed in Supplementary Information Table S3). BAP = bone-specific alkaline phos-
phatase; BVTV = bone volume fraction; NTX = N-terminal telopeptide; usCRP = ultrasensitive C-reactive protein; vBMD = volumetric bone mineral density.
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glycerol and fatty acids increased consistently (Supplementary
Information Fig. S7G). Conversely, linolenoylcarnitine (C18:3)*,
linoleoylcarnitine (C18:2)*, and sphingomyelin (d18:1/22:2,
d18:2/22:1, d16:1/24:2)* levels were reduced in the L. reuteri
group compared with the placebo group (Supplementary
Information Fig. S7H-J).
Fig 4. The metabolites identified in the case group versus the control group. (A) The class information of 104 differential metabolites is shown. (B) The
receiver operating characteristic (ROC) curve of the random forest model using 104metabolites. Area under the ROC curve (AUC) = 0.81 for control versus
case groups (n = 36, respectively). (C) The top 30 important metabolites identified by the random forest model. The color shows log2-fold change.
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Differential metabolites distinguishing the case group
from the control group
To confirm the associations between BMD and the identified
metabolites mediated by L. reuteri supplementation, we further
performed metabolomics profiling in a case–control cohort
including 120 olderwomenwith high BMD (control) and 120 older
women with very low BMD (case). In total, 240 serum samples
were collected and measured. The clinical characteristics of the
subjects in the cohort are provided in Table 2. After data normal-
ization, we obtained 1007 metabolites for downstream analyses.
We investigated the variances in the metabolomics data by PCA
and PLS-DA. The PCA results did not reveal distinct metabolomic
profiles between the case and control groups (Supplementary
Information Fig. S8A). We also examined the correlations of the
first two principal components of the PCA with measured clinical
parameters (Supplementary Information Fig. S8B). BMI andweight
were correlated with the first two principal components. In addi-
tion, the PLS-DA analysis showed better segregation of the case
and control groups (Supplementary Information Fig. S9A).
Next, the differences of metabolites between the case and
control groups were compared using linear regression models
adjusted by the confounders age and BMI. No individually signif-
icantly differential metabolites were observed (adjusted p < 0.1;
Supplementary Information Table S4). Furthermore, differential
metabolites between the case and control groups were selected
by using the cut-off of the VIP score of >1 in the PLS-DA model
and p value <0.05 in the fold changes of metabolites. A total of
104 differential metabolites were identified (Supplementary
Information Fig. S9B): 81 metabolites showed lower levels and
23 metabolites showed higher levels in the case group com-
pared with the control group, which mainly classified into lipid,
amino acid, peptide, and cofactors (Fig. 4A).
To achieve better discrimination between the case group and
control group, a random forest model was developed based on
a training set using the 104 differential metabolite abundance of
70% of the subjects selected randomly from the case and control
groups (n = 84, respectively). Performance of the random forest
model was evaluated by using a validation set (consisting of
30% of subjects selected randomly from the case and control
groups, n = 36, respectively) and scored the predictive power by
the ROC analysis. The discriminatory power of these metabolites
was calculated as the AUC. Low BMD status could be correctly
identified with an AUC of 0.81 (Fig. 4B). The variable importance
by a mean decrease in accuracy was calculated for the random
forest model. The top 30 differential metabolites ordered by
importance are given in Fig. 4C: 3-carboxy-4-methyl-5-propyl-
2-furanpropanoate (CMPF) related to fatty acid metabolism was
the most important metabolite for discrimination of the case
and control groups. Lysine and fumarate were among the top
10 important metabolites. Moreover, leucine, valine, glutamate,
gamma-glutamyl-alpha-lysine, and homoarginine were important
metabolites for the identification of low BMD.
Pathway analysis of differential metabolites between the
case and control groups
Differential metabolites between the case and control groups were
further analyzed using the web-based tool MetaboAnalyst that has
integrated pathway enrichment analysis with the topology analysis.
These differential metabolites were mapped to 38 relevant KEGG
pathways (Supplementary Information Fig. S10). The significantly
enriched metabolic pathways (p < 0.05; Table 3) were mainly
involved in amino acid metabolism, steroid hormone biosynthesis,
butanoate metabolism, and the citrate cycle. Thus, amino acid
metabolism was not only associated with low BMD but was also
affected by treatment with L. reuteri (Supplementary
Information Fig. S5). In addition, steroid hormone biosynthesis was
significantly differential between case and control groups—
consistent with the fact that steroid hormones influence bone
metabolism by regulating the balance of osteoclasts and
osteoblasts.(30-32)
Metabolites differed between the case and control groups
and simultaneously were regulated by treatment with
L. reuteri
Among 104 differential metabolites differing between the case
and control groups, 12 of them also showed differential responses
to L. reuteri supplementation (Table 4). Valine, TMAP, and isovaler-
ylcarnitine (C5) levels were higher in the control (high BMD) group
compared with the case (low BMD) group, which was consistent
with previous observations that they had increased levels after
supplementation with L. reuteri (Supplementary
Information Fig. S5). Cysteine S-sulfate levels were higher in the
control group, whereas they decreased in response to supplemen-
tation with L. reuteri (Supplementary Information Fig. S5G). Thus,
these metabolites involved in amino acid metabolism were not
only differential between the case and control groups, but also
affected by supplementation of L. reuteri. In addition, gamma-glu-
tamyl-alpha-lysine and gamma-glutamyl leucine levels were
higher in the control group, consistentwith the fact that theywere
increased by supplementation of L. reuteri (Supplementary
Information Fig. S6A, B). Moreover, deoxycarnitine levels were
higher in the control group and simultaneously rose in response
to supplementation with L. reuteri (Supplementary
Information Fig. S7F).
Discussion
Supplementation of L. reuteri was recently reported to substan-
tially reduce bone loss in older women.(10) However, the effects
of L. reuteri on humanmetabolism are still not clear. Here, we first
analyzed time-series metabolomic profiles of elderly women
with bone loss to evaluate if metabolic changes were caused
by the supplementation of L. reuteri. The study population
showed no significant differences in the clinical characteristics
between L. reuteri and placebo groups at baseline, indicating a
successful randomization. The positive correlation between cor-
tical vBMD and us-CRP was only observed at baseline, inconsis-
tent with previous findings that the CRP level was inversely
associated with BMD.(33) In addition, BMI was positively associ-
ated with us-CRP and TNF-α at both time points. This supports
the previous finding that obesity is associated with increased
inflammation.(34,35) The bone turnover markers BAP and NTx
were associated negatively with bone-related traits, such as total
tibia vBMD and cortical vBMD, which was consistent with previ-
ous results.(26-29)
Serum samples were collected from these subjects in the
placebo-controlled RCT cohort during 1-year follow-up at base-
line and 3, 6, and 12 months. Similar metabolic profiles were
observed at baseline between the L. reuteri and placebo groups.
Less variations were observed over time in the L. reuteri group by
pairwise comparisons of different time points. Overall, the meta-
bolic profiles exhibited differences between the L. reuteri and
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placebo groups at the follow-up time points. We further investi-
gated whether metabolic changes were triggered by the probi-
otic treatment, which might help understand the mechanistic
effects of L. reuteri on human metabolism. Using the cut-off of
a VIP score of >1 in the PLS-DA model and p value <0.05 in the
Wilcoxon rank-sum test, 97 metabolites showed differential
responses between the L. reuteri and placebo groups, and were
involved in multiple metabolic processes including amino acid,
peptide, and lipid metabolism. Interestingly, these differential
metabolites were clustered into mainly four different response
patterns, thus providing more insights into the biological pro-
cesses in which metabolites were consistently regulated by the
supplementation of L. reuteri.
Amino acids, including proline, threonine, and valine, showed
differential responses between the L. reuteri and placebo groups.
It had previously been reported that amino acids as signaling
molecules modulate bone turnover and are associated with
higher BMD.(36,37) Therefore, our data support that supplementa-
tion of the probiotic L. reuteri will increase the serum amino acid
levels that may regulate bone metabolism in older women. The
branched-chain amino acids (valine) and their derivatives, isova-
lerylcarnitine (C5), 2-methylbutyrylcarnitine (C5), and isovaleryl-
glycine, especially increased with the supplementation of
L. reuteri. Interestingly, isovalerylcarnitine (C5) showed a positive
correlation with total tibia vBMD at both baseline and
12 months, which suggests it may be a potential biomarker of
bone loss. The results were consistent with the rising levels of
gamma-glutamyl-amino acids, which may transport amino acids
by the γ-glutamyl cycle.(38) As seen in Fig. 5, BCAAs could be
transported into the cytoplasm by the γ-glutamyl cycle. Then,
intracellular BCAAs may stimulate osteoblast differentiation
and improve bone metabolism by activating complex 1 of the
mammalian target of rapamycin (mTORC1) directly.(39,40) It is
possible that BCAAs could also improve bone density by indi-
rectly regulating mTORC1, which plays critical roles in T-cell reg-
ulation and insulin signaling that affects bone homeostasis.(41-43)
The level of cysteine S-sulfate decreased in response to treat-
ment with L. reuteri compared with the placebo group. Simulta-
neously, the metabolite was correlated negatively with total
tibia vBMD at 12 months. Interestingly, cysteine S-sulfate is a
structural analog of glutamate that acts as an N-methyl-D-
aspartate receptor (NMDA-R) agonist.(44) A previous study has
reported expression and function of NMDA-R in osteoclasts
involved in bone resorption.(45) Thus, cysteine S-sulfate may be
a potential regulator interacting with NMDA-R that is required
for bone metabolism,(46) as illustrated in Fig. 5. In addition,
1-methyl-4-imidazoleacetate and 1-ribosyl-imidazoleacetate*
that are involved in histidine metabolism were not only regu-
lated by L. reuteri treatment, but also associated positively with
total tibia vBMD at baseline. Simultaneously, they were associ-
ated positively with TNF-α and BMI at baseline. These results sug-
gest that these two metabolites may be regulated by TNF-α,
which is known to affect bonemetabolism.(47) The levels of indo-
lepropionate and indole-3-carboxylate involved in tryptophan
metabolism were kept steady in the L. reuteri group, whereas
they increased over time in the placebo group. This is consistent
with previous reports on tryptophanmetabolites having an influ-
ence on bone remodeling.(48)
Previous studies have shown that fatty acid oxidation plays an
important role in the energy metabolism of bone.(49,50) In this
study, butyrylcarnitine (C4) and caprate (10:0), related to fatty
acid metabolism, also showed increased levels in the L. reuteri
group compared with the placebo group. Thus, the energy
produced during the β oxidation of the identified fatty acids
may promote bone formation. Notably, butyrylcarnitine (C4), a
butyrate ester of carnitine, may act as the pool and transporter
of butyrate,(51) which has previously been shown to inhibit bone
resorption and stimulate bone formation in mice through a
mechanism involving regulatory T cells andWnt10b.(6,7) Butyrate
supplementation was recently reported to increase bonemass in
WT mice and to prevent ovariectomy-induced bone loss.(52)
Thus, the robust increase in this metabolite during the whole
treatment period may explain the effect of L. reuteri in reducing
bone loss as recently shown by our research group.(10) Based
on data from an experimental study in mice, Yan and colleagues
proposed that short-chain fatty acids may restore IGF-1 levels
depleted by antibiotic treatment. IGF-1 is known to promote
skeletal growth and has effects on both bone formation and
resorption.(53) In a recent cohort study, associations between dif-
ferent metabolites and plasma IGF-1 levels were investigated in
women.(54) Serum levels of the amino acid threonine, which
was altered by L. reuteri treatment in the present study, was
found to be associated with serum IGF-1 levels, indicating that
the IGF-1 signaling pathway and pathways affected by L. reuteri
treatment could overlap, at least some extent.
Fig 5. Illustration of the hypothetical mechanism of the effects of probi-
otic Lactobacillus reuteri on bone metabolism. BCAAs could be trans-
ported by the γ-glutamyl cycle and activate complex 1 of mammalian
target of rapamycin (mTORC1). mTORC1 stimulates osteoblast differenti-
ation and improves bone health directly. In addition,mTORC1 plays a crit-
ical role in T-cell regulation and insulin signaling, which affect bone
homeostasis indirectly. Cysteine S-sulfate may be an important regulator
of bonemetabolism by interacting with NMDA-R that is involved in bone
resorption. The energy produced during the β oxidation of the identified
fatty acids may promote bone formation. Butyrylcarnitine may act as the
pool and transporter of butyrate and have potential for stimulating bone
formation. γ-glutamyl-AAs = gamma-glutamyl-amino acids; BCAAs =
branched chain amino acids; IR = insulin receptor; mTORC1 = complex
1 of mammalian target of rapamycin; NMDA-R = N-methyl-D-aspartate
receptor.
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It has previously been shown that carnitine participates in the
transportation of fatty acids into the mitochondrion where fatty
acid oxidation takes place and improves BMD by suppressing
bone turnover.(55) Moreover, sphingomyelin (d18:1/22:2,
d18:2/22:1, d16:1/24:2)* level decreased in the L. reuteri group
compared with the placebo group, which agreed with previous
results that sphingomyelin affects bone mineralization.(56,57)
To validate the associations between low BMD and the identi-
fiedmetabolites regulated by L. reuteri supplementation, we ana-
lyzed the metabolomic profiles of a case and control population
of elderly women with severe osteoporosis or high BMD. A total
of 104 differential metabolites were identified, which were
mainly involved in lipid, amino acid, peptide, and cofactors.
Using a machine-learning approach, low BMD status could be
correctly predicted with an AUC of 0.81 by a random forest
model using the validation set, showing a robust association
between these metabolites and BMD. Metabolites CMPF, lysine,
fumarate, leucine, valine, glutamate, gamma-glutamyl-alpha-
lysine, and homoarginine were the top metabolites discriminat-
ing the case and control groups. Homoarginine has been
reported to be associated with bone density previously.(58)
In addition, we found significant differences in BCAAs biosyn-
thesis and steroid hormone biosynthesis between the case (low
BMD) and control (high BMD) groups. It is well known that ste-
roid hormones, including cortisol, DHEA sulfate, and other sex
steroids, influence bone metabolism by regulating the balance
between osteoclasts and osteoblasts.(30-32) In total, 12 metabo-
lites differed between the case and control groups and were
simultaneously regulated by treatment with L. reuteri; valine, cys-
teine S-sulfate, and isovalerylcarnitine (C5) were identified.
Therefore, these metabolites may be not only potential bio-
markers of low BMD but also possible links between bone
metabolism and probiotic treatment.
It must be acknowledged that the metabolomics analysis was
not a predefined analysis determined before unblinding in the
RCT and that the number of women included in the RCT was
small, which could have influenced our results. Moreover, our
ability to identify differentially regulated metabolites could have
been affected by multiple comparisons. Although no identified
single metabolite remained significantly differentially regulated
by L. reuteri supplementation when applying a Bonferroni test
or FDR correction, the PLS-DA analysis showed a specific set of
metabolites able to segregate the L. reuteri from the placebo
group. The single differentially regulated metabolites identified
in this study, are hypothesis generating but these findings
require confirmation in future studies. Furthermore, causal rela-
tionships cannot be determined by the identified associations.
The results were obtained in older women and may not be rep-
resentative of men and other age groups.
In conclusion, metabolomic profiling was employed to
explore the effect of L. reuteri on themetabolic dynamics in older
women with bone loss. Global shifting of metabolic status was
observed during the 1-year trial. Our previous RCT found that
supplementation with probiotic L. reuteri reduces bone loss,
and our present analysis indicates that the treatment is associ-
ated with changes in amino acid, peptide, and lipid metabolism
in elderly women. Butyrylcarnitine (C4) especially exhibited a
robust increase in subjects with L. reuteri treatment, indicating
the involvement of butyrate signaling in bone metabolism. Fur-
ther studies are, however, needed to identify the mechanisms
and determine how gut microbiota changes are caused by sup-
plementation with probiotic L. reuteri and how such changes
are linked to human metabolomic dynamics.
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